Biotech Archives - Page 3 of 733

1 minute read

CEL-SCI Presents Head & Neck Cancer Data At IDDST Annual Congress In Budapest: Risk Of Death Cut In Half For Patients Treated With Multikine In The Target Population

June 18, 8:21 AM

Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors73% survival for Multikine vs 45% in the control arm at 5

CVM

1 minute read

Takeda To Present Long-Term Data From Phase 3 ADVANCE-CIDP 3 Clinical Trial Of HYQVIA In Patients With Chronic Inflammatory Demyelinating Polyneuropathy At PNS Annual Meeting

By Benzinga Newsdesk

June 18, 8:06 AM

Favorable Findings from the Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for Maintaining Stable Disease Course in CIDPADVANCE Clinical Program Reflects Takeda's

TAK

2 minute read

FDA Approves Merck’s Pneumococcal Vaccine As First Shot Designed For Adults

By Vandana Singh

June 18, 8:05 AM

The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains of bacteria. Additionally, Merck's Keytruda received FDA approval for advanced endometrial carcinoma.

MRK

1 minute read

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With NRAS-Mutant Melanoma

By Benzinga Newsdesk

June 18, 8:05 AM

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to dateFavorable mOS and mPFS demonstrated in pooled

ERAS

1 minute read

Taysha Gene Therapies Announced Longer-term Clinical Data From Ongoing REVEAL Phase 1/2 Adolescent And Adult Trial And Initial Clinical Data From REVEAL Phase 1/2 Pediatric Trial Of TSHA-102 In Rett Syndrome

By Benzinga Newsdesk

June 18, 7:40 AM

Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen

TSHA

2 minute read

Vaxart Stock Is Moving Higher After The Bell: What’s Going On?

By Adam Eckert

June 17, 4:32 PM

Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company's cash runway into 2026.

VXRT

1 minute read

Kyverna Therapeutics Presents First-In-Disease Use Of KYV-101 In Patient With Severe Stiff-Person Syndrome Published In Proceedings Of The National Academy Of Sciences

By Benzinga Newsdesk

June 17, 4:09 PM

Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option after failure to respond to conventional therapiesSignificant improvement in walking distance

KYTX

1 minute read

Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?

By Vandana Singh

June 17, 1:22 PM

BioNTech partner MediLink Therapeutics faces a partial clinical hold from the FDA on the Phase 1 trial of BNT326/YL202 for advanced non-small cell lung cancer and HR+/HER2-negative breast cancer.

BNTX

2 minute read

Pfizer’s COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading Claims

By Vandana Singh

June 17, 1:13 PM

Kansas has filed a lawsuit against Pfizer, Inc., alleging the company misled the public about the safety and effectiveness of its COVID-19 vaccine, resulting in consumer protection violations and record revenues.

PFE